Press release
What's driving the Atrial Fibrillation Drugs Market trends? Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca
Atrial Fibrillation Drugs Market
Atrial Fibrillation Drugs Market will exceed USD 17.0 billion by 2025; as per a new research report. Growing number of geriatric population and increasing prevalence of valvular diseases will boost atrial fibrillation drugs industry growth worldwide. Moreover, rising adoption rate of sedentary lifestyle coupled with increasing habit of binge eating among the millennials in developed as well as developing countries will prove to be a high impact rendering factor for the atrial fibrillation drugs market growth during forthcoming years.
Request a sample of this premium report at https://www.marketstudyreport.com/request-a-sample/2057027?utm_source=openpr.com&utm_medium=Abhijeet
Industry players having a strong foothold in the atrial fibrillation drugs market include Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca. Various recognized firms are entering in sparsely addressed high potential geographies to expand their industry presence. In addition, introduction of drug therapies in developing countries by these companies enable them to expand revenue sources and cater to unmet needs of patient population.
However, drug side effects will be one of the major reasons hindering the adoption rates in few developing and under-developed countries. Drug side effects such as severe bleeding, tiredness, etc. will continue to hamper market growth over the forecast timeframe. Also, lack of awareness regarding recent medical drug therapies for the treatment of atrial fibrillation in certain emerging nations might hamper market growth.
Anticoagulant drugs market is forecasted to grow at a lucrative rate of 3.5% over the estimation period. Anticoagulant drugs are most widely used across geographies; the need of using these drugs in the three stages of atrial fibrillation will fuel market growth. Anticoagulants have been known for many years to produce a declining rate of stroke in individuals suffering from atrial fibrillation. Moreover, increasing venture capital investment of firms in the manufacturing of therapeutic drugs will further boost product demand. Hence, the aforementioned factors will boost anticoagulants growth in the global atrial fibrillation drugs market.
The use of atrial fibrillation drugs in paroxysmal condition accounted for revenue of USD 7,095.8 million in the year 2018. Paroxysmal atrial fibrillation occurs when there are irregular electric pathways in the heart and the heart is not pumping enough oxygen-rich blood around the body. The likelihood of suffering from paroxysmal atrial fibrillation increases with age. The most suitable treatment for paroxysmal atrial fibrillation is anticoagulants or blood thinners. Hence, rise in population of baby boomers coupled with increasing prevalence of patients suffering from paroxysmal atrial fibrillation will augment market growth.
Application of atrial fibrillation drugs in heart rhythm control will witness a considerable decline at -2.3% over the forecast timeframe owing to decreasing use of these drugs for restoration and maintenance of sinus rhythm in patients with atrial fibrillation. According to the recent data launch of new oral anticoagulants in the market and rise in preference of physicians to prescribe anticoagulants in case of atrial fibrillation will impede the use of antiarrhythmic drugs in heart rhythm control. As per the American Heart Association, currently around 2.7 million to 6 million Americans suffer from some form of atrial fibrillation. Hence, the rising incidence of the disease will boost atrial fibrillation drugs demand but will witness decline in the use of atrial fibrillation drugs in heart rhythm control.
Injectable atrial fibrillation drugs segment is estimated to grow at 2.4% over the projection period. The growth is attributed to its wide use in patients suffering from acute atrial fibrillation that are forbidden to take drugs orally. Hence, increase in such cases have augmented the segment growth of injectable atrial fibrillation drugs.
Hospitals segment was valued at around USD 6,583.2 million in the year 2018. Hospitals as an end use segment are emerging as one of the preferred healthcare settings for atrial fibrillation care in various countries across the globe. Increasing popularity of this setting in developed countries owing to availability of drug therapies coupled with rising supply agreements of drugs between manufacturing firms and hospitals will strongly propel the growth of atrial fibrillation drugs market in hospitals.
U.S. atrial fibrillation drugs market will witness a growth of 2.4% during the forecast period. Increasing number of major industry players in U.S. facilitates efficient treatment option for patients with atrial fibrillation. Moreover, rising prevalence of chronic diseases such as diabetes, hypertension, etc. will further augment U.S. atrial fibrillation market growth.
China atrial fibrillation drugs market was valued at around USD 805.4 million in the year 2018. The country offers lucrative growth opportunity owing to the unmet needs in large addressable geographical markets. The countrys increasing acceptance of private clinics and development of multi-specialty hospitals would propel industry growth over the forecast period.
Request a discount on standard prices of this premium report at https://www.marketstudyreport.com/check-for-discount/2057027?utm_source=openpr.com&utm_medium=Abhijeet
Report Content
Chapter 1. Methodology
Chapter 2. Executive Summary
Chapter 3. Atrial Fibrillation Drugs Industry Insights
Chapter 4. Atrial Fibrillation Drugs Market, By Product
Chapter 5. Atrial Fibrillation Drugs Market, By Atrial Fibrillation Type
Chapter 6. Atrial Fibrillation Drugs Market, By Application
Chapter 7. Atrial Fibrillation Drugs Market, By Route of Administration
Chapter 8. Atrial fibrillation Drugs Market, By End-use
Chapter 9. Atrial Fibrillation Drugs Market, By Region
Chapter 10. Company Profiles
10.1. AstraZeneca
10.2. Boehringer Ingelheim
10.3. Bristol-Myers Squibb
10.4. Daiichi Sankyo
10.5. GlaxoSmithKline
10.6. Johnson and Johnson (JanssenOrtho)
10.7. Mitsubishi Tanabe Pharma
10.8. Pfizer
10.9. Portola Pharmaceuticals
10.10. Sanofi
buying decision on this premium report https://www.marketstudyreport.com/enquiry-before-buying/2057027?utm_source=openpr.com&utm_medium=Abhijeet
Contact Us:
Market Study Report LLC
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: https://www.marketstudyreport.com
Blog: https://www.marketstudyreport.com/blog
About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release What's driving the Atrial Fibrillation Drugs Market trends? Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca here
News-ID: 1787813 • Views: …
More Releases from marketstudyreport.com
Load Bank Market Growth Prospectus by 2028 - Business Opportunities by ASCO Powe …
A concise assortment of data on the 'Load Bank Market' offers an exhaustive study targeting current market trends influencing the business across assorted regions. Significant details related to market size, market share, applications, and statistics are put together to convey an ensemble prediction of the industry. The research further focuses on comprehensive competitor analysis in addition to highlighting growth strategies embraced by market leaders.
Load Bank Market Size was estimated…
Agriculture Equipment Market is Expected to Reach USD 161640 Million by 2028 - J …
Global Agriculture Equipment Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of the market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report.
Global Agriculture Equipment Market Size was estimated at USD 114110 million in 2021 and is projected to reach USD 161640 million by 2028, exhibiting a CAGR of…
Electric Vehicle Market Size to grow at a CAGR of 23.5% through 2028| Tesla Inc. …
Global Electric Vehicle Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report.
The electric vehicles (EVs) market is estimated to witness a robust growth rate of 23.5% during the period 2019-2028.
The operation is done to stop ligament tears and…
Fuel Cell Air Compressor Market is Expected to Reach USD 512.3 Million by 2028 - …
Global Fuel Cell Air Compressor Market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of market with the geographical landscape, demand, remuneration scale, and growth of this vertical have also been included in this report.
Global Fuel Cell Air Compressor Market Size was estimated at USD 215.1 million in 2021 and is projected to reach USD 512.3 million by 2028, exhibiting…
More Releases for Atrial
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to…
Atrial Fibrillation Market
Atrial Fibrillation Market is predicted to grow at a double digit CAGR over the forecast period (2017 to 2023). Atrial fibrillation, also denoted as AF, is an irregular or fast heart rhythm. It raises the dangers of chest pain, heart strokes, congestive heart failure, or cardiac discomfort. The typical indications of AF are dizziness, confusion, fainting, or tiredness.
Therapeutic advancements and the burgeoning aged populace also drive the industry. Supportive clinical…
Atrial Fibrillation Stroke Treatment Market Segmentation By Atrial Fibrillation …
The arrhythmia problem occurs due to irregular heartbeats which can cause atrial fibrillation stoke. The irregular manner (increase pattern or lower pattern of heart beats) of heart beating pattern can cause atrial fibrillation stroke. The atrial fibrillation stroke causes major problem of heart and increase heart related problem. The patient which are suffering from atrial fibrillation effect two chamber of heart and atria present below the heart will lead to…
Atrial Fibrillation Market Opportunity Analysis, 2018-2026
Atrial fibrillation, also known as A-fib or AF, is an irregular heartbeat exemplified by rapid and abnormal beating of the heart. Most episodes of atrial fibrillation have no symptoms or fewer symptoms such as intermittent heart palpitations, lightheadedness, fainting, chest pain, and shortness of breath. Atrial fibrillation is linked with an elevated risk of heart failure, stroke, and dementia. The disease is a kind of supraventricular tachycardia. Risk factors associated…
Atrial Septal Defect Market Future Opportunities2017 - 2025
Global Atrial Septal Defect Market: Outlook
Atrial septal defect is one of the most common congenital cardiac diseases and usually affects women more than men. It is characterized by a hole or defect in the interatrial septum that separates the heart’s two upper chambers, i.e., atria. The opening in the septum usually closes when the baby is born, but in few cases if the opening does not close, the hole…
Atrial Fibrillation Market Analysis, Forecast, and Assessment 2026
Increasing prevalence of common diseases and conditions such as obesity, diabetes, hypertension, etc., are leading to the risk of various heart problems. Moreover, the rise in people suffering from high blood pressure, and valvular heart disease due to the rheumatic fever are some of the most common risk factors for atrial fibrillation. Along with the increasing number of people suffering from atrial fibrillation, especially among the geriatric population. There has…
